Stanford University
Showing 41-60 of 78 Results
-
Vinod Menon
Rachael L. and Walter F. Nichols, MD, Professor and Professor, by courtesy, of Education and of Neurology
Current Research and Scholarly InterestsEXPERIMENTAL, CLINICAL AND THEORETICAL SYSTEMS NEUROSCIENCE
Cognitive neuroscience; Systems neuroscience; Cognitive development; Psychiatric neuroscience; Functional brain imaging; Dynamical basis of brain function; Nonlinear dynamics of neural systems. -
Mark Mercola
Professor of Medicine (Cardiovascular) and, by courtesy, of Chemical and Systems Biology
BioDr. Mercola is Professor of Medicine and Professor in the Stanford Cardiovascular Institute. He completed postdoctoral training at the Dana-Farber Cancer Institute and Harvard Medical School, was on the faculty in the Department of Cell Biology at Harvard Medical School for 12 years, and later at the Sanford-Burnham-Prebys Institute and Department of Bioengineering at the University of California, San Diego before relocating to Stanford in 2015.
Prof. Mercola is known for identifying many of the factors that are responsible for inducing and forming the heart, including the discovery that Wnt inhibition is a critical step in cardiogenesis that provided the conceptual basis and reagents for the large-scale production of cardiovascular tissues from pluripotent stem cells. He has collaborated with medicinal chemists, optical engineers and software developers to pioneer the use of patient iPSC-cardiomyocytes for disease modeling, safety pharmacology and drug development. His academic research is focused on developing and using quantitative high throughput assays of patient-specific cardiomyocyte function to discover druggable targets for preserving contractile function in heart failure and promoting regeneration following ischemic injury. He co-established drug screening and assay development at the Conrad Prebys Drug Discovery Center (San Diego), which operated as one of 4 large screening centers of the US National Institutes of Health (NIH) Molecular Libraries screening initiative and continues as one of the largest academic drug screening centers.
Prof. Mercola received an NIH MERIT award for his work on heart formation. He holds numerous patents, including describing the invention of the first engineered dominant negative protein and small molecules for stem cell and cancer applications. He serves on multiple editorial and advisory boards, including Vala Sciences, Regencor, The Ted Rogers Centre for Heart Research and the Human Biomolecular Research Institute. His laboratory is funded by the National Institutes of Health (NIH), California Institute for Regenerative Medicine, Phospholamban Foundation and Fondation Leducq. -
Ross Metzger
Sr Res Scientist-Basic Life, Pediatrics - Cardiology
Current Research and Scholarly InterestsDevelopment, maintenance, and repair of the pulmonary circulation
-
Everett Meyer
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy), of Pediatrics (Stem Cell Transplantation) and, by courtesy, of Surgery (Abdominal Transplantation)
Current Research and Scholarly InterestsResearch focus in T cell immunotherapy and T cell immune monitoring using high-throughput sequencing and genomic approaches, with an emphasis on hematopoietic stem cell transplantation, the treatment of graft-versus-host disease and immune tolerance induction.
-
Timothy Meyer
Stanford University Professor of Nephrology, Emeritus
Current Research and Scholarly InterestsInadequate removal of uremic solutes contributes to widespread illness in the more than 500,000 Americans maintained on dialysis. But we know remarkably little about these solutes. Dr. Meyer's research efforts are focused on identifying which uremic solutes are toxic, how these solutes are made, and how their production could be decreased or their removal could be increased. We should be able to improve treatment if we knew more about what we are trying to remove.
-
Emmanuel Mignot, MD, PhD
Craig Reynolds Professor of Sleep Medicine and Professor, by courtesy, of Genetics and of Neurology
Current Research and Scholarly InterestsThe research focus of the laboratory is the study of sleep and sleep disorders such as narcolepsy and Kleine Levin syndrome. We also study the neurobiological and genetic basis of the EEG and develop new tools to study sleep using nocturnal polysomnography. Approaches mostly involve human genetic studies (GWAS, sequencing), EEG signal analysis (deep learning), and immunology (narcolepsy is an autoimmune disease of the brain). We also work on autoimmune encephalitis.
-
Carlos Milla
Professor of Pediatrics (Pulmonary Medicine) and, by courtesy, of Medicine (Pulmonary and Critical Care Medicine)
Current Research and Scholarly InterestsAt Stanford University I developed and currently direct the CF Translational Research Center. The overarching goal of the center is to provide the groundwork to streamline, accelerate, and promote the translation of basic discoveries into effective therapies and interventions to benefit patients affected by cystic fibrosis. My laboratory group currently has three main lines of investigation: respiratory cell biology in CF; remote biochemical monitoring; and lung physiology in young children.
-
Vaishali Mittal
Postdoctoral Scholar, Dermatology
BioVaishali Mittal, MD is a Postdoctoral Clinical Fellow in the Department of Dermatology at Stanford University under the guidance of Dr. Jean Y. Tang.
Her current research is focused on epidermolysis bullosa (EB), a group of rare diseases that cause the skin and mucous membranes to blister easily. She is involved in conducting long-term clinical trials examining the application of an autologous, gene-corrected keratinocyte sheet for the treatment of recessive dystrophic EB (RDEB). In addition, she is currently leading several research projects, including investigation of genotype-phenotype associations in multiple subtypes of EB, creation of an online platform for EB patients/families and investigators to collaborate together on research, and development of an online genetic registry for EB patients using a novel, home-based genetic testing kit.
Vaishali received her medical degree from Stanford University School of Medicine and completed her internship at Beth Israel Deaconess Medical Center/Brockton Hospital. -
Masashi Miyauchi
Postdoctoral Scholar, Stem Cell Biology and Regenerative Medicine
BioMasashi Miyauchi, MD, PhD, is a physician-scientist specializing in hematology, oncology, immunology, and stem cell biology, with over a decade of experience in clinical hematology and oncology. Dr. Miyauchi's academic career commenced at Kyoto University, where he obtained his MD in Medicine. He furthered his expertise with a PhD in Internal Medicine from The University of Tokyo, Graduate School of Medicine. Following his comprehensive clinical training and professional appointments at The University of Tokyo Hospital, Dr. Miyauchi embarked on a postdoctoral journey at Stanford University in the Nakauchi lab, starting in July 2019.
Dr. Miyauchi's clinical training is extensive, including a Senior Residency in Internal Medicine and a Clinical Fellowship in Hematology and Oncology at The University of Tokyo Hospital. This period was complemented by his participation in a Cancer Professional Training Plan. After completing his clinical fellowship, Dr. Miyauchi has served in various pivotal roles at The University of Tokyo Hospital and The University of Tokyo. His positions as a clinically-focused Project Assistant Professor and Assistant Professor in the Department of Hematology and Oncology have enabled him to contribute significantly to pioneering research and education for the next wave of medical professionals.
In his PhD research, Dr. Miyauchi specialized in the disease modeling of cancers and cancer stem cells, employing cancer patient-specific induced pluripotent stem cells (iPSCs). His work with iPSCs notably includes scalable ex vivo manufacturing of human neutrophils. In his postdoctoral research under the guidance of Dr. Hiromitsu Nakauchi in Genetics at Stanford, Dr. Miyauchi has been concentrating on developing a stable hematopoietic stem cell (HSC) expansion system in both mouse and human models. His research is focused on exploring the potential applications of this expansion system, underlining his commitment to advancing the fields of stem cell biology, regenerative medicine and oncology. -
Daria Mochly-Rosen
George D. Smith Professor of Translational Medicine
Current Research and Scholarly InterestsTwo areas: 1. Using rationally-designed peptide inhibitors to study protein-protein interactions in cell signaling. Focus: protein kinase C in heart and large GTPases regulating mitochondrial dynamics in neurodegdenration. 2. Using small molecules (identified in a high throughput screens and synthetic chemistry) as activators and inhibitors of aldehyde dehydrogenases, a family of detoxifying enzymes, and glucose-6-phoshate dehydrogenase, in normal cells and in models of human diseases.
-
Everett J. Moding, MD, PhD
Assistant Professor of Radiation Oncology (Radiation Therapy)
Current Research and Scholarly InterestsMy laboratory performs translational research using analysis of human samples to identify critical mediators of treatment resistance that can be validated in preclinical models and targeted to enhance the efficacy of cancer therapy.
-
Matteo Amitaba Mole'
Assistant Professor of Obstetrics and Gynecology (Reproductive & Stem Cell Biology)
Current Research and Scholarly InterestsThe research focus of our laboratory is centered on investigating the complex process of human embryo implantation. Due to the limited availability of suitable model systems and inability to directly observe this process in vivo, this has been traditionally referred to as the enigmatic stage of human embryonic development.
The successful implantation of an embryo is crucial for the establishment of a healthy pregnancy. During the transition between the first and second week of gestation, the human embryo must securely implant into the maternal uterus, initiating development of the placenta to receive necessary nutrients and oxygen for its growth until birth.
However, the process of implantation in humans is highly susceptible to failure, with a significant percentage of embryos unable to develop beyond this stage leading to early miscarriages. This clinically observed "implantation barrier" often requires patients to undergo numerous cycles of IVF treatment, with no guarantee of a successful pregnancy outcome.
The primary objective is to increase the understanding of maternal-embryo interactions initiated at implantation, with the goal of developing clinical interventions to address the high incidence of implantation failures underlying pre-clinical miscarriages.
